

Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes

Lianne M. Reus, Bogdan Pasaniuc, Danielle Posthuma, Toni Boltz, International FTD-Genomics Consortium, Yolande A.L. Pijnenburg, and Roel A. Ophoff

ABSTRACT

BACKGROUND: The etiology of frontotemporal dementia (FTD) is poorly understood. To identify genes with predicted expression levels associated with FTD, we integrated summary statistics with external reference gene expression data using a transcriptome-wide association study approach.

METHODS: FUSION software was used to leverage FTD summary statistics (all FTD: $n = 2154$ cases, $n = 4308$ controls; behavioral variant FTD: $n = 1337$ cases, $n = 2754$ controls; semantic dementia: $n = 308$ cases, $n = 616$ controls; progressive nonfluent aphasia: $n = 269$ cases, $n = 538$ controls; FTD with motor neuron disease: $n = 200$ cases, $n = 400$ controls) from the International FTD-Genomics Consortium with 53 expression quantitative loci tissue type panels ($n = 12,205$; 5 consortia). Significance was assessed using a 5% false discovery rate threshold.

RESULTS: We identified 73 significant gene–tissue associations for FTD, representing 44 unique genes in 34 tissue types. Most significant findings were derived from dorsolateral prefrontal cortex splicing data ($n = 19$ genes, 26%). The 17q21.31 inversion locus contained 23 significant associations, representing 6 unique genes. Other top hits included *SEC22B* (a gene involved in vesicle trafficking), *TRGV5*, and *ZNF302*. A single gene finding (*RAB38*) was observed for behavioral variant FTD. For other clinical subtypes, no significant associations were observed.

CONCLUSIONS: We identified novel candidate genes (e.g., *SEC22B*) and previously reported risk regions (e.g., 17q21.31) for FTD. Most significant associations were observed in dorsolateral prefrontal cortex splicing data despite the modest sample size of this reference panel. This suggests that our findings are specific to FTD and are likely to be biologically relevant highlights of genes at different FTD risk loci that are contributing to the disease pathology.

<https://doi.org/10.1016/j.biopsych.2020.12.023>

Frontotemporal dementia (FTD) is a heterogeneous neurodegenerative disorder characterized by frontal and/or temporal patterns of atrophy. Clinically, patients with FTD present with the behavioral variant of FTD (bvFTD) or language variants such as semantic dementia (SD) and progressive nonfluent aphasia (PNFA) (1). In 10% of all cases, FTD co-occurs with motor neuron diseases (FTD-MND) (2).

Where FTD is mostly sporadic (80%), approximately 20% of all FTD cases are familial, with the most common Mendelian mutations including the hexanucleotide repeat expansion at the *C9ORF72* locus on chromosome 9 and mutations in microtubule-associated protein tau (*MAPT*) and progranulin (*GRN*) genes in and near the chromosome 17q21 inversion locus (3–7). Genome-wide association studies (GWASs) in FTD have also identified genetic risk variants, each having small associations with disease risk (8–11). The number of known FTD disease susceptibility loci remains small owing to limited power for discovery in the relatively small sample sizes of the GWASs so far with $n_{\text{cases}} < 5000$. At this time, it is poorly

understood how genetic risk variants for FTD exert effects on etiology, while such knowledge is essential for understanding disease pathology and the development of therapeutic interventions.

Genetic risk variants identified in GWASs are often located in noncoding regions with and without regulatory motifs outside the protein encoding sequences (12). These risk variants are likely to predispose individuals to disease susceptibility by modulating messenger RNA expression levels through local (*cis*) or distal (*trans*) expression quantitative trait loci (eQTL) (13). The FTD risk variant rs302652 nearby *RAB38* is a local eQTL, decreasing *RAB38* gene expression in monocytes (11) and potentially influencing bvFTD disease risk by modulating *RAB38* gene expression levels in specific brain areas. However, the joint effects of genetic risk loci for FTD on (differential) gene expression across multiple tissue types are unclear.

Transcriptome-wide association studies (TWASs) have emerged as a way to identify associations between traits and

SEE COMMENTARY ON PAGE e37

gene expression. The most common TWAS methods include PrediXcan, summary data-based Mendelian randomization, and FUSION (14–16). TWAS leverage the combined effects of multiple single nucleotide polymorphisms (SNPs), on either the individual level (PrediXcan and summary data-based Mendelian randomization) or the summary level (s-PrediXcan and FUSION), on gene expression, thereby increasing power to find novel associations over a traditional GWAS when gene expression mediates risk (14–16). Imputation of the genetic control of gene expression is now widely used to decipher how GWAS-identified alleles may contribute to disease risk, and to identify specific candidate genes through which this effect is regulated. In this study, we performed a multitissue TWAS on sporadic FTD and its clinical subtypes to identify genes whose changes in expression play a role in FTD and to identify tissue types relevant to FTD. As a secondary aim of the study, we performed a TWAS-based enrichment analysis and explored whether FTD shows overlap in differential expression with neuropsychiatric disorders that show clinical overlap with FTD.

METHODS AND MATERIALS

GWAS Summary Statistics

GWAS summary statistics from the International-FIG Consortium (IFGC) (<https://ifgcsite.wordpress.com>) on FTD ($n = 2154$ cases, $n = 4308$ controls) and the FTD clinical subtypes bvFTD ($n = 1377$ cases, $n = 2754$ controls), SD ($n = 308$ cases, $n = 616$ controls), PNFA ($n = 269$ cases, $n = 538$ controls), and FTD-MND ($n = 200$ cases, $n = 400$ controls) were used (Table S1 in Supplement 2). Written informed consent was obtained from all participants according to the Declaration of Helsinki. For all study sites, the study was approved by the medical ethics committee.

Preprocessing and quality check procedures have been described previously (11). SNPs were converted from chr:bp to rsID coordinates using Phase 3 1000 Genomes Project data (17). Summary statistics were quality checked and converted to LD-score format using the `munge_stats.py` utility from LDSC, leaving 1,068,995 SNPs for final analysis for all phenotypes (18) (see Supplemental Methods in Supplement 1).

eQTL Reference Panels

Local (*cis*) eQTL datasets from 5 different cohorts ($n = 12,205$) on 53 tissue types were downloaded from the FUSION website (<http://gusevlab.org/projects/fusion>) (Table 1). The 5 cohorts included the CommonMind Consortium (CMC) ($n = 452$) (19), the Netherlands Twin Registry (NTR) ($n = 1247$) (20), the Cardiovascular Risk in Young Finns Study (YFS) ($n = 1264$) (21), the Metabolic Syndrome in Men Study (METSIM) ($n = 562$) (22), and the Genotype Tissue Expression Project (GTEx) version 7 (<https://gtexportal.org/home/datasets>) ($n = 752$). Local eQTLs were calculated by leveraging gene expression with genetic variation data (i.e., SNPs within ± 1 Mb of the transcriptional start site of the gene). More detailed information on genotyping and gene expression analyses for these datasets have been described previously: CMC (23), NTR, YFS, METSIM (15), and GTEx (24).

Local eQTL datasets from tissue types less relevant to FTD (e.g., blood) were included in this study because local eQTLs

are highly conserved across tissues (25) and eQTL datasets with nonbrain tissues consist of substantially larger sample sizes, thereby maximizing power to detect significant associations between local gene expression and FTD GWAS SNPs.

Functional Mapping and Annotation

To examine the proportion of noncoding variants among FTD-risk SNPs, we annotated SNPs from the IFGC GWAS on FTD using Functional Mapping and Annotation (FUMA) (<https://fuma.ctglab.nl>) (26). The most significant ($p < 5 \times 10^{-6}$) SNPs and SNPs in linkage disequilibrium (LD) ($r^2 \geq .6$) with these were used for further inspection using 1000 Genomes Project data (17). Lead SNPs were defined as being independent from each other at $r^2 > .1$. LD blocks of independent SNPs were merged into a genomic locus if they were closely located to each other (i.e., < 250 kb).

Lead and correlated SNPs were annotated for potential regulatory functions (RegulomeDB) (27), 15-core chromatin state predicted by ChromHMM (28), functional consequences on gene functions annotated by ANNOVAR (29), and deleteriousness score (Combined Annotation Dependent Depletion) (30). To test for enrichment of functional consequences of lead and correlated SNPs (as estimated with ANNOVAR), we performed a Fisher's exact test using a 5% false discovery rate (FDR) significance threshold (see <https://fuma.ctglab.nl/tutorial#annov>). The enrichment value was calculated as the proportion of SNPs with an annotation divided by the proportion of SNPs with an annotation relative to all available SNPs in Phase 3 1000 Genomes Project data (17).

Statistical Analysis

TWAS Analysis. To identify genes whose local-regulated expression is associated with FTD and its clinical subtypes (i.e., bvFTD, SD, PNFA, and FTD-MND), we performed TWAS analyses using FUSION software (<http://gusevlab.org/projects/fusion>) with default settings (15). FUSION estimates the genetic correlation between local gene expression and FTD by integrating GWAS summary statistics with external gene expression reference panel data while accounting for LD structure among SNPs [using Phase 3 1000 Genomes Project data (17)]. To account for LD structure, we used 1000 Genomes (all ancestries) data as LD reference panel.

To study whether GWAS SNPs colocalized with eQTLs, we performed a Bayesian colocalization analysis for all associations with $p_{\text{TWAS uncorrected}} < .05$ using the COLOC package in R (<https://cran.r-project.org/web/packages/coloc>) (31) implemented in FUSION. A joint analysis was performed to identify which genes are conditionally independent.

TWAS results are presented including the major histocompatibility (MHC) locus because the FTD GWAS included genome-wide significant loci within the MHC region (11). Results on gene-tissue associations per phenotype (i.e., FTD, bvFTD, SD, PNFA, and FTD-MND) were corrected for multiple comparisons using a 5% FDR significance threshold. Significant TWAS loci were identified as novel if the strongest FTD-associated SNP was not nominally significant ($p > .05$) in the IFGC GWAS (11) within ± 1 Mb of the transcriptional start site of the gene's region.

Table 1. Descriptive Statistics for Tissue Reference Panels and TWAS Results

Study	Reference Panel	Subjects, N^a	Genes, N^b	FTD TWAS Significant Genes, n	Behavioral FTD TWAS Significant Genes, n
CMC	Brain: Dorsolateral prefrontal cortex	452	5244	5	0
CMC	Brain: Dorsolateral prefrontal cortex (splicing)	452	7514 (3221)	19 (13 unique)	0
GTEX	Adipose: Subcutaneous	385	7669 (7668)	1	1
GTEX	Adipose: Visceral (omentum)	313	5765 (5763)	1	0
GTEX	Adrenal gland	175	4252 (4251)	2	0
GTEX	Artery: Aorta	267	6040	1	0
GTEX	Artery: Coronary	152	3026	2	0
GTEX	Artery: Tibial	388	7732 (7730)	2	0
GTEX	Brain: Amygdala	88	1710	0	0
GTEX	Brain: Anterior cingulate cortex (BA24)	109	2523	1	0
GTEX	Brain: Caudate (basal ganglia)	144	3418	0	0
GTEX	Brain: Cerebellar hemisphere	125	4131 (4130)	2	0
GTEX	Brain: Cerebellum	154	5513	0	0
GTEX	Brain: Cortex	136	3761	0	0
GTEX	Brain: Frontal cortex (BA9)	118	2934	1	0
GTEX	Brain: Hippocampus	111	2129	0	0
GTEX	Brain: Hypothalamus	108	2147	1	0
GTEX	Brain: Nucleus accumbens (basal ganglia)	130	3032	0	0
GTEX	Brain: Putamen (basal ganglia)	111	2638	0	0
GTEX	Brain: Spinal cord (cervical C1)	83	1892	1	0
GTEX	Brain: Substantia nigra	80	1505	0	0
GTEX	Breast: Mammary tissue	251	4701 (4700)	1	0
GTEX	Blood: EBV-transformed lymphocytes	117	2558 (2557)	0	0
GTEX	Transformed fibroblasts	300	6957 (6956)	1	1
GTEX	Colon: Sigmoid	203	4559 (4558)	1	1
GTEX	Colon: Transverse	246	4935 (4934)	1	1
GTEX	Esophagus: Gastroesophageal junction	213	4563 (4562)	1	1
GTEX	Esophagus: Mucosa	358	7551 (7549)	1	0
GTEX	Esophagus: Muscularis	335	7287 (7286)	2	1
GTEX	Heart: Atrial appendage	264	5316	1	0
GTEX	Heart: Left ventricle	272	4750	1	0
GTEX	Liver	153	2711	0	1
GTEX	Lung	383	7270 (7268)	2	0
GTEX	Minor salivary gland	85	1681	0	0
GTEX	Muscle: Skeletal	491	6990 (6989)	3	0
GTEX	Nerve: Tibial	361	9064 (9062)	2	0
GTEX	Ovary	122	2620 (2619)	0	1
GTEX	Pancreas	220	4768 (4767)	2	0
GTEX	Pituitary	157	4122 (4121)	2	0
GTEX	Prostate	132	2600	1	0
GTEX	Skin: Not sun exposed (suprapubic)	335	6984 (6983)	1	0
GTEX	Skin: Sun exposed (lower leg)	414	8343 (8342)	2	0
GTEX	Small intestine: Terminal ileum	122	2664	0	0
GTEX	Spleen	146	4161	0	0
GTEX	Stomach	237	4145 (4143)	0	0
GTEX	Testis	225	8685 (8682)	1	0
GTEX	Thyroid	399	9229 (9225)	2	0

Table 1. Continued

Study	Reference Panel	Subjects, N^a	Genes, N^b	FTD TWAS Significant Genes, n	Behavioral FTD TWAS Significant Genes, n
GTEEx	Uterus	101	1972	0	0
GTEEx	Vagina	106	1852	0	0
GTEEx	Whole blood	369	1898	2	0
METSIM	Adipose	563	4458	4	0
NTR	Peripheral blood	1247	2356	0	0
YFS	Whole blood	1264	5568 (5567)	0	0
Total	–	–	246,320 (241,893 non-MHC, 233,420 unique)	73 (67 unique)	8

No significant gene–tissue interactions were observed for semantic dementia, progressive nonfluent aphasia, and FTD with motor neuron diseases.

BA, Brodmann area; CMC, CommonMind Consortium; EBV, Epstein–Barr virus; FTD, frontotemporal dementia; GTEEx, Genotype Tissue Expression Project; METSIM, Metabolic Syndrome in Men Study; NTR, Netherlands Twin Registry; TWAS, transcriptome-wide association study; YFS, Cardiovascular Risk in Young Finns Study.

^aNumber of subjects included in reference panel study.

^bNumber of genes that could be estimated. Numbers in parentheses depict the number of unique genes that could be estimated.

Mediated Expression Score Regression Analysis. To estimate the proportion of disease heritability mediated by local gene expression, we performed a mediated expression score regression (MESRC) analysis per tissue type, excluding SNPs located on the MHC locus (<https://github.com/douglasyao/mesc>) (32). Here, we define h^2_{med} as heritability mediated by local gene expression, h^2_g as disease heritability, and h^2_{med}/h^2_g as the proportion of heritability mediated by local gene expression. First, for each gene, local heritability scores were estimated while accounting for LD structure. Genes were partitioned into bins according to their local heritability because this has been shown to provide unbiased h^2_{med}/h^2_g estimates. Second, we estimated h^2_{med}/h^2_g from expression scores estimated in the previous step and GWAS summary statistics on FTD. Because MESRC produces biased estimates for eQTL reference panels with small sample sizes, only eQTL datasets with sample sizes >300 ($n = 17$) were included.

Enrichment Analysis. Competitive enrichment analysis on FTD TWAS results was performed using TWAS-based gene set enrichment analysis (TWAS-GSEA) (<https://github.com/opain/TWAS-GSEA>) (33). TWAS-GSEA is an adapted method of GWAS-based enrichment analysis implemented in MAGMA software (34). In brief, this method examines whether TWAS results are enriched for specific pathways while accounting for LD structure. Per phenotype, TWAS-GSEA was performed simultaneously for all 53 eQTL datasets. The file used as eQTL reference panel for the TWAS-GSEA analysis included unique gene identifiers only; if genes were present in multiple local eQTL datasets, the gene with the best prediction of expression (as estimated by cross-validated R^2 [MODEL CV.R2]) was used in the GSEA. Gene identifiers in TWAS result files were converted to Entrez ID format using the biomaRt package in R, resulting in 15,004 (14,813 non-MHC) unique Entrez IDs for FTD and all clinical FTD subtypes. TWAS results were tested for enrichment across 6778 Gene Ontology biological process gene sets. Per phenotype, results were corrected for the number of gene sets using a 5% FDR significance threshold.

Data Availability. The GWAS summary statistics on FTD can be acquired via the IFGC (<https://ifgcsite.wordpress.com/data-access>). Local eQTL reference weights can be downloaded from the FUSION website (<http://gusevlab.org/projects/fusion>).

RESULTS

Most Risk Variants for FTD Are Located in Noncoding Regions

For FTD, FUMA annotated 3103 SNPs from 13 independent lead SNPs located in 10 genomic risk loci. These SNPs showed enrichment for intronic (50.2%, $p_{enrichment} = 2.98 \times 10^{-120}$), intronic noncoding RNA (24.3%, $p_{enrichment} = 3.15 \times 10^{-124}$), intergenic (19.3%, $p_{enrichment} = 0$), and 5'UTR (0.75%, $p_{enrichment} = 1.61 \times 10^{-6}$) regions, whereas only 1.4% of all SNPs were located in exonic regions ($p_{enrichment} = .32$) (Table S2 in Supplement 2). Most SNPs (93.1%) were located in open chromatin regions (range of minimum chromatin state across 127 tissue/cell types = 1–7), and 11.4% of the annotated SNPs had potential regulatory elements, as indicated by a RegulomeDB score below 2 (Figure S1 in Supplement 1).

Predicted Gene Expression Levels Show 73 Associations With FTD

Predicted gene expression levels in 53 tissue types (range of genes per tissue type = 1505–9229) were tested for association with FTD. We identified 73 significant gene–tissue associations for FTD, representing 44 (40 non-MHC) unique genes in 34 tissue types (Table 1, Table S3 in Supplement 2, Figure 1, and Figure 2). In total, 39.7% (29/73) of these transcriptome-wide significant associations had supporting evidence from colocalization analyses (Table S4 in Supplement 2). The strongest genic FTD TWAS associations included *ARL17B* on chromosome 17 (brain cerebellar hemisphere $p_{FDR} = 9.02 \times 10^{-22}$), *ZNF302* on chromosome 19 (dorsolateral prefrontal cortex [DLPFC] splicing data $p_{FDR} = 5.80 \times 10^{-8}$), *LRR37A* (lung $p_{FDR} = 1.58 \times 10^{-5}$), *SEC22B* on




Figure 1. Miami plot on FTD TWAS (top) and GWAS (bottom). In total, 44 unique genes were associated with FTD across 34 tissue types. Each point depicts a distinct gene–tissue association. TWAS hits with supporting evidence from colocalization analysis are highlighted in blue. The red line depicts the significance threshold; $p_{\text{FDR}} < .05$ for TWAS and $p < 5 \times 10^{-8}$ for GWAS. FDR, false discovery rate; FTD, frontotemporal dementia; GWAS, genome-wide association study; TWAS, transcriptome-wide association study.

chromosome 1 (thyroid $p_{\text{FDR}} = 2.28 \times 10^{-3}$), and *TRGV5P* on chromosome 17 (cells transformed fibroblasts $p_{\text{FDR}} = 2.39 \times 10^{-3}$) (Table 2). Of all transcriptome-wide significant genes with supporting colocalization evidence, only the association of *SEC22B* with FTD was novel, showing no evidence for association in the FTD GWAS (minimal p within ± 1 Mb of the gene's region = 6.14×10^{-2}) (11) (Table S5 in Supplement 2).

One region of interest is 17q21.31 on chromosome 17, which contained 23 significant associations, representing 6 unique genes (i.e., *ARL17B*, *KANSL1-AS1*, *LRRC37A*, *MAPT*, *MAPT-AS1*, and *NSFP1*). This locus is an inversion polymorphism that has been associated previously with neurodegenerative tauopathies but also with psychiatric disorders such as autism spectrum disorder (33,35). Gene expressions of most gene–tissue pairs were highly correlated except for *KANSL1-AS1*, *MAPT*, and *MAPT-AS1* (Figure S2 in Supplement 1). For the majority of significant associations in 17q21.31 ($n = 16$, 69.6%), colocalization analysis provided evidence for a shared causal genetic variant between gene expression and FTD (Table S4 in Supplement 2).

Another region was 7p14.1, for which predicted gene expression of *TRGV5* and its pseudogene *TRGV5P* achieved transcriptome-wide significance in 4 different tissue types. Colocalization analyses suggested that FTD and 7p14.1 gene expression share a single causal association (Table S4 in Supplement 2).

Most TWAS Associations Were Detected in DLPFC Splicing Data

The brain-derived reference panels contributed the most to the significant associations between gene expression and FTD (43.8%, 32 gene–tissue associations), with the majority derived from DLPFC splicing data (19 splicing variants, 13 unique, all outside MHC). A previous study showed that a larger sample size and increased number of measured genes of the eQTL reference panel correlates to a higher number of significant hits (36). Despite the modest sample size ($n_{\text{sample}} = 452$) and number of measured genes ($n_{\text{genes unique}} = 3221$, $n_{\text{genes total}} = 7514$), DLPFC splicing data accounted for 26% of all transcriptome-wide hits, thereby exceeding the number of significant hits compared with eQTL tissue types with larger sample sizes (e.g., 0% for YFS whole blood, $n_{\text{sample}} = 1264$) and more measured genes (e.g., 3% for thyroid, $n_{\text{genes unique}} = 9225$, $n_{\text{genes total}} = 9229$) (Figure S3 and Figure S4 in Supplement 1). Accordingly, FTD TWAS results showed significant enrichment for DLPFC splicing data ($p = 7.31 \times 10^{-3}$) (Table S6 in Supplement 2).

MESC analysis showed that a substantial proportion of FTD heritability was mediated by the local component of gene expression levels (mean $h^2_{\text{med}} = 35 \pm 4.7\%$). The tibial nerve had the highest heritability mediated by local gene expression levels (mean $h^2_{\text{med}} = 59.5 \pm 2.2\%$), potentially reflecting a genetic component underlying the comorbidity underlying FTD and motor neuron diseases. For DLPFC




Figure 2. Heatmap of z scores of genes with at least one transcriptome-wide significant association with FTD. FTD transcriptome-wide associations demonstrate tissue-shared and tissue-specific effects. The association of imputed gene expression of genes located on region 17q21.31 (depicted in light blue) with FTD seems to be preserved across most reported tissue types, albeit not statically significant. On the other hand, none of the 13 unique (splicing) variants in the DLPFC CMC data was significant in other datasets. Transcriptome-wide significant associations ($p_{FDR} < .05$) are depicted with an asterisk. Blank squares indicate that gene weights were not available in the reference panel. CMC, CommonMind Consortium; DLPFC, dorsolateral prefrontal cortex; FDR, false discovery rate; FTD, frontotemporal dementia; GTEx, Genotype Tissue Expression Project; METSIM, Metabolic Syndrome in Men Study; NTR, Netherlands Twin Registry; YFS, Cardiovascular Risk in Young Finns Study.

splicing data, the mean h^2_{med} was $43.8 \pm 8.5\%$, whereas for the eQTL panel with the largest sample size (i.e., YFS whole blood data) this was $12.6 \pm 7.4\%$. A full overview of local mediated heritability is presented in [Figure S5](#) in [Supplement 1](#) (see SNP heritability estimates in [Table S1](#) in [Supplement 2](#)).

Predicted Gene Expression Levels on Clinical Subtypes Separately Show Association With bvFTD Only

Predicted gene expression levels in 53 tissue types (range of genes per tissue type = 1505–9229) were tested for association with bvFTD, SD, PNFA, and FTD-MND. Gene expression

Table 2. Transcriptome-wide Significant Associations With Supporting Evidence From Colocalization Analysis

Location	Min p (TWAS)	Min p (GWAS) ^a	Jointly Significant	Marginally Significant
17.q21.31	1.83×10^{-26}	5.94×10^{-5}	<i>ARL17B, LRRC37A, NSFP1</i>	<i>ARL17B, KANSL1-AS1, LRRC37A, NSFP1</i>
13.q34	5.56×10^{-7}	2.30×10^{-3}	<i>ATP11A</i>	
6.p21.33	1.00×10^{-5}	6.49×10^{-4}	<i>C4A</i>	
3.q23	1.26×10^{-6}	3.07×10^{-3}	<i>CLSTN2</i>	
2.q35	4.57×10^{-6}	9.48×10^{-4}	<i>KRT8P30</i>	
10.q21.2	1.24×10^{-5}	2.69×10^{-2}	<i>RHOBTB1</i>	
1.p12	3.61×10^{-7}	8.88×10^{-2}	<i>SEC22B</i>	
9.q22.31	7.21×10^{-6}	6.14×10^{-2}	<i>SUSD3</i>	
7.p14.1	3.89×10^{-7}	2.24×10^{-2}	<i>TRGV5</i>	<i>TRGV5, TRGV5P</i>
19.q13.11	3.06×10^{-12}	2.63×10^{-2}	<i>ZNF302</i>	<i>ZNF302</i>
19.q13.41	9.09×10^{-6}	6.04×10^{-2}	<i>ZNF468</i>	

GWAS, genome-wide association study; TWAS, transcriptome-wide association study.

^aMin p (GWAS) represents the p value for the top single nucleotide polymorphism association within ± 1 Mb of the transcriptional site of the gene's region.

of *RAB38* on chromosome 11 was significantly associated with bvFTD risk in 8 of 25 tissue panels (colon sigmoid $p_{FDR} = 4.02 \times 10^{-4}$, range of significant gene–tissue associations $p_{FDR} = 4.02 \times 10^{-4}$ to 4.37×10^{-2}) (Figure 3, Figure S6 in Supplement 1, and Table S7 in Supplement 2). Colocalization supported model 4 with a range posterior probability 4 of 0.64 to 1.0 (range posterior probability 3 = 0.003–0.04) (Table S8 in Supplement 2). The former GWAS on bvFTD showed nominal evidence for the association of *RAB38* with FTD (rs302668 odds ratio = 0.81 [95% confidence interval = 0.71–0.91]; $p_{GWAS} = 2.44 \times 10^{-7}$) (11). For SD, PNFA, and FTD-MND, no significant transcriptome-wide associations were observed (Figures S7, S8, and S9 in Supplement 1 and Tables S9–S14 in Supplement 2).

Implicated Genes Highlight Involvement of Amino Acid Transport in FTD Pathogenesis

Full competitive results for the enrichment analysis on FTD and its clinical subtypes are presented in Tables S15 to S24 in Supplement 2. TWAS results for FTD were significantly enriched for sulfur amino acid transport (with MHC $p_{FDR} = .04$, without MHC $p_{FDR} = .03$) (Figures S11 and S12 in Supplement 1). For all other gene sets and traits, no gene sets were significant after FDR correction.

No Genetic Correlations Were Observed Between Gene Expression FTD and Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Primary Psychiatric Disorders

Given the similarities between FTD and several neuropsychiatric disorders, we explored the genetic correlations between the predicted gene expression for FTD and Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), schizophrenia, autism spectrum disorder, and major depressive disorder using RHOGE (37) (see Supplemental Methods in Supplement 1). No significant correlations were observed after FDR correction (Tables S25 and S26 in Supplement 2 and Figure S13 in Supplement 1).

DISCUSSION

In this study, we aimed to better understand the genetic etiology of sporadic FTD by identifying genes whose expression plays a role in FTD, using a TWAS approach with increased power of detecting loci compared with a traditional GWAS. We identified 73 significant gene–tissue associations for FTD, representing 44 unique genes in 34 tissue types. The 17q21.31 inversion region was replicated as risk region for FTD. *SEC22B* was identified as likely novel risk gene for FTD. Interestingly, most associations were derived from splicing data of the DLPFC, a brain region that is nearly universally involved in FTD, thereby providing some biological validation to the multitissue TWAS approach in FTD. Moreover, these findings highlight the importance of splicing events for disease risk (38). Our results indicate that a large proportion of FTD risk loci modulate gene expression levels, and we highlight these genes as potential candidates for functional follow-up studies.

The majority of FTD risk variants were located in noncoding regions, demonstrating that these variants likely have regulatory functions. A total of 44 genes were identified as differentially expressed in FTD. We replicated the 17q21.31 locus as risk factor for FTD. This region contained 23 significant associations from 6 different genes: *ARL17B*, *KANSL1-AS1*, *LRRC37A*, *NSFP1*, *MAPT-AS1*, and *MAPT*. Mutations in the latter gene, *MAPT*, are identified as one of the most common Mendelian mutations implicated in familial FTD (6). The 17q21.31 region contains a common inversion polymorphism and has been associated not only with several neurodegenerative disorders (e.g., progressive supranuclear palsy, corticobasal degeneration, AD, FTD) but also with psychiatric disorders such as autism spectrum disorder (33,35,39–42). Previous research has shown that different haplotypes of the 17q21.31 inversion affect expression of 17q21.31 genes in blood and different brain regions (43). Here, we highlight the role of differential gene expression of 17q21.31 genes across several tissue types in the pathogenesis of FTD.

Another implicated gene was *SEC22B* on chromosome 1, which showed evidence for differential gene expression in FTD without achieving genome-wide significance in the corresponding FTD GWAS ($p > .05$ within ± 1 Mb of *SEC22B*).




Figure 3. Regional association plot of *RAB38* for behavioral variant frontotemporal dementia. The top panel shows all the genes in the locus. The transcriptome-wide marginally significant associated genes are highlighted in blue, and those that are jointly significant (i.e., *RAB38* in colon sigmoid) are highlighted in green. The bottom panel shows a Manhattan plot of the genome-wide association study data before (gray) and after (blue) conditioning on the green genes. This locus goes from being genome-wide significant to being nonsignificant after conditioning on the predicted expression of *RAB38*. chr, chromosome.

SEC22B codes for a protein that plays an important role in vesicle trafficking between the Golgi apparatus and the endoplasmic reticulum, autophagy, and membrane fusion. The latter is essential for the development of the nervous system, including axonal and dendritic growth (44). Little is known about the precise role of *SEC22B* in neurodegeneration, but differential expression of this gene in the brain has been associated with normal aging and AD (45,46).

We found increased *C4A* gene expression to be significantly associated with FTD. The *C4* gene has two functionally different isoforms (i.e., *C4A* and *C4B*, both of which can vary in structure and copy number) and is located on the MHC locus, a locus strongly associated with immune-related processes. Structural variation in *C4A/B* has been associated with schizophrenia, probably affecting synaptic pruning (47,48). The potential role of *C4* (structure) in the etiology of FTD is not fully understood yet. Human postmortem and mice model studies on FTD demonstrate an association between upregulated *C4A* gene expression and aggregation of transactive response DNA-binding protein 43 (TDP), one of the most common pathological subtypes underlying FTD (49,50). Although this would suggest a specific relationship between upregulated *C4A* gene expression and FTD pathology, increased *C4A* gene expression has also been observed in AD and schizophrenia (51).

We explored the genetic correlation between predicted gene expression for FTD and primary psychiatric disorders AD and ALS. Although FTD and psychiatric disorders overlap with respect to symptoms and affected neuroanatomical regions, we found no indications for an overlapping expression profile (52,53). We further did not observe a significant overlap of predicted gene expression for FTD with both AD and ALS. Although previous studies have reported a shared genetic architecture between FTD and ALS (54), our results suggest that

the known clinical association between FTD and ALS (in ~10% of all cases) might not be driven by an overlap in gene expression. Altogether, this suggests that at least part of the FTD TWAS signal is specific for FTD rather than generic to neuropsychiatric disorders.

Proteins differentially expressed in FTD showed enrichment for the transport of sulfur amino acids (e.g., methionine, cysteine), a process essential for the synthesis of antioxidants. For example, transport of L-cystine (i.e., oxidized form of cysteine) is needed for the production of antioxidant glutathione in the brain (55). Sulfur amino acids are sensitive to oxidative modifications by reactive oxygen-containing species. A balance between the production of reactive oxygen-containing species and antioxidants protects cells against invaders. However, an imbalance leads to increased oxidative stress, which is particularly damaging to cells in high demand of oxygen such as neuronal cells (56). Increased oxidative stress has been associated with aging and has been observed in several disorders, including FTD (56–58).

Despite the modest sample size of the DLPFC CMC reference panel, the DLPFC contributed to significantly more transcriptome-wide findings compared to other tissue types, thereby highlighting the topology-specific neurodegenerative nature of FTD. MESC analysis, an approach to examine the genome-wide distribution of heritability, showed that the tibial nerve had the largest proportion of heritability mediated by local gene expression, which may reflect the comorbidity of FTD with motor neuron disorders. However, motor neuron disorders typically present with the degeneration of both upper and lower motor neurons, while most (but not all) studies indicate that sensory neurons are spared (59,60). While tibial nerve degeneration has been observed in motor neuron disorders, this nerve contains both motor and sensory axons and Schwann cells, making it possibly less specific as tissue of

interest for motor neuron disorders (61). Therefore, current MES-C results should be validated using reference weights of upper and lower motor neuron tissue types.

We also observed various associations outside the brain, potentially highlighting the importance of other organ systems in FTD. In line with this, other organ systems, such as the gastrointestinal and musculoskeletal systems, have been associated with FTD (62,63). On the other hand, we included local eQTL data from many tissue types—also those that are seemingly less disease relevant—to increase power and to include as many genes in this exploratory study. As a result, we might not have detected the true mechanism of disease owing to a shared cross-tissue regulatory architecture of eQTLs between the tissue types related and nonrelated to FTD (25,64). This is illustrated by our finding on bvFTD, for which we identified differential regulatory gene expression only of *RAB38* in tissue types outside the brain. Because *RAB38* is expressed throughout the brain (<https://gtexportal.org/home/gene/RAB38>) but is not available in the brain tissue panels we used, we hypothesize that differential expression of *RAB38* in the brain contributes to bvFTD disease risk as well. To gain a deeper understanding of molecular mechanisms underlying FTD, future TWAS studies should increase the sample sizes of eQTL reference panels of disease-relevant tissue types and refine tissue-specific information with, for instance, cell type-specific features.

This study is a starting point for bridging the gap between genetic variation and disease pathogenesis involving specific genes in FTD. Nevertheless, several limitations should be taken into account. First, where TWAS increases power over a traditional GWAS, the small sample size of the current FTD GWAS ($n = 2154$ cases, $n = 4308$ controls) still reduces the power to find novel transcriptome-wide associations. As such, future TWASs on FTD should be performed using FTD GWAS summary statistics with a larger sample size, because this would increase not only the power to detect true associations, but also the robustness of results on tissue enrichment and genetic correlations. A second major limitation is that this study does not address the pathological heterogeneity in FTD. The most common pathological subtypes of FTD include abnormal aggregation of tau (frontotemporal lobar degeneration [FTLD]-tau) and FTLD-TDP (65). Because we performed a TWAS on the clinical entity of FTD, this study provides insights only into generic mechanisms underlying FTD but not into specific mechanisms underlying pathological subtypes. Additional studies in postmortem verified FTD cases are required to gain more insight into distinct mechanisms underlying pathological subtypes of FTD. Moreover, our results should be replicated using independent *cis* eQTL datasets to exclude the possibility that presented findings reflect false-positive findings. Finally, it should be noted that TWAS or colocalization analysis cannot be used for causal inference (64). Therefore, it is essential that our efforts will be extended to functional validation to further understand the relationship between FTD and genes reported in this study.

Results presented in this study could be used as a point of reference in future genetic association studies on FTD. We provide evidence for the contribution of many genes, with both tissue-shared and tissue-specific effects, to the pathogenesis of FTD, including potential novel (i.e., *SEC22B*) and previously

reported (e.g., 17q21.31 inversion region, *C4A*) FTD risk loci. Most associations were detected in DLPFC splicing data, but tissues outside the brain may be involved in FTD as well. However, functional validation is needed because TWASs are sensitive to detecting associations not relevant for disease if the disease-relevant tissue is not well represented across reference panels. Identifying which biological processes are genetically influenced by FTD is important for understanding the disease etiology, and eventually for the development of treatments.

ACKNOWLEDGMENTS AND DISCLOSURES

This project has been supported by a personal Alzheimer Nederland fellowship for LMR called “Genetic and functional overlap between behavioural variant frontotemporal dementia and psychiatric disorders” (Grant No. WE.15-2018-11). YALP received a personal fellowship from the Dutch Brain Foundation. Research of the Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc Fonds. Analyses were supported by the EU-PRISM Project (www.prism-project.eu), which received funding from the Innovative Medicines Initiative 2 Joint Undertaking (Grant No. 115916). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations.

Funding sources had no role in the design and conduct of the study, data collection, data analysis, and data interpretation or in the writing and approval of this article.

We thank and acknowledge the IFGC. We also acknowledge Nick Mancuso (Keck School of Medicine, University of Southern California) for his part in calculating the reference weights for the TWAS analysis.

A previous version of this article was published as a preprint on bioRxiv: <https://doi.org/10.1101/2020.06.23.166355>.

The authors report no biomedical financial interests or potential conflicts of interest.

ARTICLE INFORMATION

From the Department of Neurology (LMR, YALP), Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam; Department of Complex Trait Genetics (DP), Center for Neurogenomics and Cognitive Research, Vrije Universiteit Amsterdam, Amsterdam; and Department of Psychiatry (RAO), Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands; Department of Human Genetics (BP, TB, RAO), Department of Pathology and Laboratory Medicine (BP), and Department of Computational Medicine (BP), David Geffen School of Medicine, University of California, Los Angeles, and Center for Neurobehavioral Genetics (RAO), University of California, Los Angeles, Los Angeles, California.

IFGC authors: Raffaele Ferrari (principal investigator), Dena G. Hernandez, Michael A. Nalls, Jonathan D. Rohrer, Adaikalavan Ramasamy, John B.J. Kwok, Carol Dobson-Stone, William S. Brooks, Peter R. Schofield, Glenda M. Halliday, John R. Hodges, Olivier Piguet, Lauren Bartley, Elizabeth Thompson, Isabel Hernández, Agustín Ruiz, Mercè Boada, Barbara Borroni, Alessandro Padovani, Carlos Cruchaga, Nigel J. Cairns, Luisa Benussi, Giuliano Binetti, Roberta Ghidoni, Gianluigi Forloni, Daniela Galimberti, Chiara Fenoglio, Maria Serpente, Elio Scarpini, Jordi Clarimón, Alberto Lleó, Rafael Blesa, Maria Landqvist Waldö, Karin Nilsson, Christer Nilsson, Ian R.A. Mackenzie, Ging-Yuek R. Hsiung, David M.A. Mann, Jordan Grafman, Christopher M. Morris, Johannes Attems, Timothy D. Griffiths, Ian G. McKeith, Alan J. Thomas, Pietro Pietrini, Edward D. Huey, Eric M. Wassermann, Atik Baborie, Evelyn Jaros, Michael C. Tierney, Pau Pastor, Cristina Razuquin, Sara Ortega-Cubero, Elena Alonso, Robert Perneczky, Janine Diehl-Schmid, Panagiotis Alexopoulos, Alexander Kurz, Innocenzo Rainero, Elisa Rubino, Lorenzo Pinessi, Ekaterina Rogaeva, Peter St. George-Hyslop, Giacomina Rossi, Fabrizio Tagliavini, Giorgio Giaccone, James B. Rowe, Johannes C.M. Schlachetzki, James Uphill, John Collinge,

Simon Mead, Adrian Danek, Vivianna M. Van Deerlin, Murray Grossman, John Q. Trojanowski, Julie van der Zee, Christine Van Broeckhoven, Stefano F. Cappa, Isabelle Le Ber, Didier Hannequin, Véronique Golfier, Martine Verclletto, Alexis Brice, Benedetta Nacmias, Sandro Sorbi, Silvia Bagnoli, Irene Piaceri, Jørgen E. Nielsen, Lena E. Hjerfjord, Matthias Riemenschneider, Manuel Mayhaus, Bernd Ibach, Gilles Gasparoni, Sabrina Pichler, Wei Gu, Martin N. Rossor, Nick C. Fox, Jason D. Warren, Maria Grazia Spillantini, Huw R. Morris, Patrizia Rizzu, Peter Heutink, Julie S. Snowden, Sara Rollinson, Anna Richardson, Alexander Gerhard, Amalia C. Bruni, Raffaele Maletta, Francesca Frangipane, Chiara Cupidi, Livia Bernardi, Maria Anfossi, Maura Gallo, Maria Elena Conidi, Nicoletta Smirne, Rosa Rademakers, Matt Baker, Dennis W. Dickson, Neill R. Graff-Radford, Ronald C. Petersen, David Knopman, Keith A. Josephs, Bradley F. Boeve, Joseph E. Parisi, William W. Seeley, Bruce L. Miller, Anna M. Karydas, Howard Rosen, John C. van Swieten, Elise G.P. Dopper, Harro Seelaar, Yolande A.L. Pijnenburg, Philip Scheltens, Giancarlo Logroscino, Rosa Capozzo, Valeria Novelli, Annibale A. Puca, Massimo Franceschi, Alfredo Postiglione, Graziella Milan, Paolo Sorrentino, Mark Kristiansen, Hwei-Hsin Chiang, Caroline Graff, Florence Pasquier, Adeline Rollin, Vincent Deramecourt, Florence Lebert, Dimitrios Kapogiannis, Luigi Ferrucci, Stuart Pickering-Brown, Andrew B. Singleton, John Hardy, and Parastoo Momeni.

Address correspondence to Lianne M. Reus, M.Sc., at l.reus@amsterdamumc.nl.

Received Jul 6, 2020; revised Dec 1, 2020; accepted Dec 29, 2020.

Supplementary material cited in this article is available online at <https://doi.org/10.1016/j.biopsych.2020.12.023>.

REFERENCES

- Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, *et al.* (2011): Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain* 134:2456–2477.
- Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC (2011): Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review. *J Neurol Neurosurg Psychiatry* 82:476–486.
- Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, *et al.* (2011): A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* 72:257–268.
- DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, *et al.* (2011): Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* 72:245–256.
- Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, *et al.* (2006): Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. *Nature* 442:916–919.
- Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, *et al.* (1998): Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature* 393:702–705.
- Greaves CV, Rohrer JD (2019): An update on genetic frontotemporal dementia. *J Neurol* 266:2075–2086.
- Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-Radford NR, *et al.* (2010): Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. *Nat Genet* 42:234–239.
- Diekstra FP, Van Deerlin VM, van Swieten JC, Al-Chalabi A, Ludolph AC, Weishaupt JH, *et al.* (2014): C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: A genome-wide meta-analysis. *Ann Neurol* 76:120–133.
- Pottier C, Ren Y, Perkerson RB 3rd, Baker M, Jenkins GD, van Blitterswijk M, *et al.* (2019): Genome-wide analyses as part of the international FTLTDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLTDP. *Acta Neuropathol* 137:879–899.
- Ferrari R, Hernandez DG, Nalls MA, Rohrer JD, Ramasamy A, Kwok JBJ, *et al.* (2014): Frontotemporal dementia and its subtypes: A genome-wide association study. *Lancet Neurol* 13:686–699.
- Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, *et al.* (2012): Systematic localization of common disease-associated variation in regulatory DNA. *Science* 337:1190–1195.
- Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ (2010): Trait-associated SNPs are more likely to be eQTLs: Annotation to enhance discovery from GWAS. *PLoS Genet* 6:e1000888.
- Gamazon ER, Wheeler HE, Shah KP, Mozaffari SV, Aquino-Michaels K, Carroll RJ, *et al.* (2015): A gene-based association method for mapping traits using reference transcriptome data. *Nat Genet* 47:1091–1098.
- Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BW, *et al.* (2016): Integrative approaches for large-scale transcriptome-wide association studies. *Nat Genet* 48:245–252.
- Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, *et al.* (2016): Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat Genet* 48:481–487.
- 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, *et al.* (2015): A global reference for human genetic variation. *Nature* 526:68–74.
- Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the Psychiatric Genomics Consortium, *et al.* (2015): LD score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* 47:291–295.
- Fromer M, Roussos P, Sieberts SK, Johnson JS, Kavanagh DH, Perumal TM, *et al.* (2016): Gene expression elucidates functional impact of polygenic risk for schizophrenia. *Nat Neurosci* 19:1442–1453.
- Wright FA, Sullivan PF, Brooks AI, Zou F, Sun W, Xia K, *et al.* (2014): Heritability and genomics of gene expression in peripheral blood. *Nat Genet* 46:430–437.
- Laaksonen J, Taipale T, Seppala I, Raitoharju E, Mononen N, Lyytikainen LP, *et al.* (2017): Blood pathway analyses reveal differences between prediabetic subjects with or without dyslipidaemia. The Cardiovascular Risk in Young Finns Study. *Diabetes Metab Res Rev* 33:e2914.
- Laakso M, Kuusisto J, Stancakova A, Kuulasmaa T, Pajukanta P, Lusa AJ, *et al.* (2017): The Metabolic Syndrome in Men Study: A resource for studies of metabolic and cardiovascular diseases. *J Lipid Res* 58:481–493.
- Gusev A, Mancuso N, Won H, Kousi M, Finucane HK, Reshef Y, *et al.* (2018): Transcriptome-wide association study of schizophrenia and chromatin activity yields mechanistic disease insights. *Nat Genet* 50:538–548.
- GTEX Consortium (2015): Human genomics: The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans. *Science* 348:648–660.
- GTEX Consortium; Laboratory, Data Analysis, and Coordinating Center—Analysis Working Group; Statistical Methods Groups—Analysis Working Group; Enhancing GTEx Groups; NIH Commons Fund; NIH/NCI, *et al.* (2017): Genetic effects on gene expression across human tissues. *Nature* 550:204–213.
- Watanabe K, Taskesen E, van Bochoven A, Posthuma D (2017): FUMA: Functional mapping and annotation of genetic associations. *Nat Commun* 8:1826.
- Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, *et al.* (2012): Annotation of functional variation in personal genomes using RegulomeDB. *Genome Res* 22:1790–1797.
- Ernst J, Kellis M (2012): ChromHMM: Automating chromatin-state discovery and characterization. *Nat Methods* 9:215–216.
- Wang K, Li M, Hakonarson H (2010): ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 38:e164.
- Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M (2019): CADD: Predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res* 47:D886–D894.
- Plagnol V, Smyth DJ, Todd JA, Clayton DG (2009): Statistical independence of the colocalized association signals for type 1 diabetes and RPS26 gene expression on chromosome 12q13. *Biostatistics* 10:327–334.

32. Yao DW, O'Connor LJ, Price AL, Gusev A (2020): Quantifying genetic effects on disease mediated by assayed gene expression levels. *Nat Genet* 52:626–633.
33. Pain O, Pocklington AJ, Holmans PA, Bray NJ, O'Brien HE, Hall LS, *et al.* (2019): Novel insight into the etiology of autism spectrum disorder gained by integrating expression data with genome-wide association statistics. *Biol Psychiatry* 86:265–273.
34. de Leeuw CA, Mooij JM, Heskes T, Posthuma D (2015): MAGMA: Generalized gene-set analysis of GWAS data. *PLoS Comput Biol* 11:e1004219.
35. Li Y, Chen JA, Sears RL, Gao F, Klein ED, Karydas A, *et al.* (2014): An epigenetic signature in peripheral blood associated with the haplotype on 17q21.31, a risk factor for neurodegenerative tauopathy. *PLoS Genet* 10:e1004211.
36. Gamazon ER, Zwinderman AH, Cox NJ, Denys D, Derks EM (2019): Multi-tissue transcriptome analyses identify genetic mechanisms underlying neuropsychiatric traits. *Nat Genet* 51:933–940.
37. Mancuso N, Shi H, Goddard P, Kichaev G, Gusev A, Pasaniuc B (2017): Integrating gene expression with summary association statistics to identify genes associated with 30 complex traits. *Am J Hum Genet* 100:473–487.
38. Li Yi, van de Geijn B, Raj A, Knowles DA, Petti AA, Golan D, *et al.* (2016): RNA splicing is a primary link between genetic variation and disease. *Science* 352:600–604.
39. Myers AJ, Kaleem M, Marlowe L, Pittman AM, Lees AJ, Fung HC, *et al.* (2005): The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. *Hum Mol Genet* 14:2399–2404.
40. Webb A, Miller B, Bonasera S, Boxer A, Karydas A, Wilhelmsen KC (2008): Role of the tau gene region chromosome inversion in progressive supranuclear palsy, corticobasal degeneration, and related disorders. *Arch Neurol* 65:1473–1478.
41. Gandal MJ, Zhang P, Hadjimichael E, Walker RL, Chen C, Liu S, *et al.* (2018): Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. *Science* 362:eaat8127.
42. Mishra A, Ferrari R, Heutink P, Hardy J, Pijnenburg Y, Posthuma D, *et al.* (2017): Gene-based association studies report genetic links for clinical subtypes of frontotemporal dementia. *Brain* 140:1437–1446.
43. de Jong S, Chepelev I, Janson E, Strengman E, van den Berg LH, Veldink JH, *et al.* (2012): Common inversion polymorphism at 17q21.31 affects expression of multiple genes in tissue-specific manner. *BMC Genomics* 13:458.
44. Petkovic M, Jemaïel A, Daste F, Specht CG, Izeddin I, Vorkel D, *et al.* (2014): The SNARE Sec22b has a non-fusogenic function in plasma membrane expansion. *Nat Cell Biol* 16:434–444.
45. Zhao Y, Tan W, Sheng W, Li X (2016): Identification of biomarkers associated with Alzheimer's disease by bioinformatics analysis. *Am J Alzheimers Dis Other Demen* 31:163–168.
46. Berchtold NC, Coleman PD, Cribbs DH, Rogers J, Gillen DL, Cotman CW (2013): Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer's disease. *Neurobiol Aging* 34:1653–1661.
47. Kamitaki N, Sekar A, Handsaker RE, De Rivera H, Tooley K, Morris DL, *et al.* (2020): Complement genes contribute sex-biased vulnerability in diverse disorders. *Nature* 582:577–581.
48. Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, *et al.* (2016): Schizophrenia risk from complex variation of complement component 4. *Nature* 530:177–183.
49. Chen-Plotkin AS, Geser F, Plotkin JB, Clark CM, Kwong LK, Yuan W, *et al.* (2008): Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. *Hum Mol Genet* 17:1349–1362.
50. Wu LS, Cheng WC, Chen CY, Wu MC, Wang YC, Tseng YH, *et al.* (2019): Transcriptopathies of pre- and post-symptomatic frontotemporal dementia-like mice with TDP-43 depletion in forebrain neurons. *Acta Neuropathol Commun* 7:50.
51. McCarthy N, Laws SM, Porter T, Burnham SC, Moses EK, Jablensky A (2019): Increased predicted C4A expression is associated with cognitive deficit in both schizophrenia and Alzheimer's disease. *Eur Neuropsychopharmacol* 29(suppl 3):S871.
52. Pose M, Cetekovich M, Gleichgericht E, Ibanez A, Torralva T, Manes F (2013): The overlap of symptomatic dimensions between frontotemporal dementia and several psychiatric disorders that appear in late adulthood. *Int Rev Psychiatry* 25:159–167.
53. Zamboni G, Huey ED, Krueger F, Nichelli PF, Grafman J (2008): Apathy and disinhibition in frontotemporal dementia: Insights into their neural correlates. *Neurology* 71:736–742.
54. Karch CM, Wen N, Fan CC, Yokoyama JS, Kouri N, Ross OA, *et al.* (2018): Selective genetic overlap between amyotrophic lateral sclerosis and diseases of the frontotemporal dementia spectrum. *JAMA Neurol* 75:860–875.
55. McBean GJ, Flynn J (2001): Molecular mechanisms of cystine transport. *Biochem Soc Trans* 29:717–722.
56. Haque MM, Murale DP, Kim YK, Lee JS (2019): Crosstalk between oxidative stress and tauopathy. *Int J Mol Sci* 20:1959.
57. Stadtman ER, Van Remmen H, Richardson A, Wehr NB, Levine RL (2005): Methionine oxidation and aging. *Biochim Biophys Acta* 1703:135–140.
58. Palluzzi F, Ferrari R, Graziano F, Novelli V, Rossi G, Galimberti D, *et al.* (2017): A novel network analysis approach reveals DNA damage, oxidative stress and calcium/cAMP homeostasis-associated biomarkers in frontotemporal dementia. *PLoS One* 12:e185797.
59. van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, *et al.* (2017): Amyotrophic lateral sclerosis. *Lancet* 390:2084–2098.
60. Hammad M, Silva A, Glass J, Sladky JT, Benatar M (2007): Clinical, electrophysiologic, and pathologic evidence for sensory abnormalities in ALS. *Neurology* 69:2236–2242.
61. Simon NG, Lagopoulos J, Paling S, Pfluger C, Park SB, Howells J, *et al.* (2017): Peripheral nerve diffusion tensor imaging as a measure of disease progression in ALS. *J Neurol* 264:882–890.
62. Ahmed RM, Irish M, Piguat O, Halliday GM, Ittner LM, Farooqi S, *et al.* (2016): Amyotrophic lateral sclerosis and frontotemporal dementia: Distinct and overlapping changes in eating behaviour and metabolism. *Lancet Neurol* 15:332–342.
63. Ikegami S, Harada A, Hirokawa N (2000): Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice. *Neurosci Lett* 279:129–132.
64. Wainberg M, Sinnott-Armstrong N, Mancuso N, Barbeira AN, Knowles DA, Golan D, *et al.* (2019): Opportunities and challenges for transcriptome-wide association studies. *Nat Genet* 51:592–599.
65. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, *et al.* (2010): Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: An update. *Acta Neuropathol* 119:1–4.